Key Highlights
- Effective May 1, 2024: Paul Keel will become the CEO of Envista Holdings, also joining the Board of Directors.
- Experienced Leader: Keel has held significant roles at 3M, Smiths Group plc, and has an MBA from Harvard Business School.
- Focus on Innovation: Plans to enhance digital, personalized dental care underpinned by the Envista Business System.
Source: PR Newswire
Notable Quotes
- “Paul’s strong track record…makes him the right leader for Envista at this stage in our growth journey,” – Scott Huennekens, Chairman at Envista
- “It’s a great honor to lead Envista at this exciting time in our deep and rich history,” – Paul Keel, Incoming CEO at Envista Holdings
SoHC's Take
Paul Keel’s appointment as CEO of Envista Holdings marks a pivotal moment for the company, poised for transformative growth. His extensive background in leadership and innovation across renowned global firms provides him the unique insights required to drive Envista towards new heights in the evolving dental industry. With his past experiences aligning perfectly with Envista’s mission, Keel’s tenure is expected to herald a new era of technological advancements and enhanced customer-focused solutions in dental care. This strategic leadership transition seems perfectly timed as Envista aims to further its legacy as a leader in digital and personalized dental solutions.
Related

Tandem Diabetes Care Appoints Jean-Claude Kyrillos as COO
Key Highlights Jean-Claude "JC" Kyrillos appointed as Executive Vice President and COO, effective June 21, 2024.Brings over 20 years of global executive leadership in medical device, digital health, and healthcare management.Previously held key roles at Envista Holdings, Qualcomm Life, Becton Dickinson, and ResMed Inc.Source: Business Wire Notable Quotes “JC brings…

Xeris Biopharma Announces CEO Succession Plan, John P. Shannon to Lead as New CEO
Key Highlights Paul R. Edick to retire as CEO and Chairman effective August 1, 2024.John P. Shannon appointed as new CEO and Board member.Marla S. Persky named Chairperson of the Board.Xeris anticipates over $47 million in Q2 2024 revenue.Paul R. Edick to serve as a senior advisor through February 2026.Source:…

Elucid Names Kelly Huang, PhD, as New CEO to Lead Commercial Launch
Key Highlights Elucid appoints Kelly Huang, PhD, as new CEO.Huang brings extensive market planning and commercialization expertise.Elucid prepares for commercial launch of PlaqueIQ software.Recent $80 million Series C funding to support expansion.Source: Business Wire Notable Quotes “Kelly brings a history of successful commercialization and growth experience to Elucid at a…